Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4957 USD | +0.55% | +2.19% | -8.76% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Financials (USD)
Sales 2024 * | 36.94M | Sales 2025 * | 64.14M | Capitalization | 102M |
---|---|---|---|---|---|
Net income 2024 * | -109M | Net income 2025 * | -82M | EV / Sales 2024 * | 3.87 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.61 x |
P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-1.6
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.29% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | -5.36% | ||
1 week | -4.46% | ||
Current month | -26.44% | ||
1 month | -29.87% | ||
3 months | +11.59% | ||
6 months | +1.52% | ||
Current year | -9.26% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 58 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 16 M€ | -7.62% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.4957 | +0.55% | 814 613 |
24-04-24 | 0.493 | -5.36% | 1,157,568 |
24-04-23 | 0.5209 | +2.12% | 2,278,588 |
24-04-22 | 0.5101 | -0.27% | 1,267,414 |
24-04-19 | 0.5115 | +5.44% | 1,050,146 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.26% | 102M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.75% | 22.2B | |
-16.53% | 21.23B | |
-9.03% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- SGMO Stock